Alaris Royalty (TSE:AD) Given “Sector Perform” Rating at National Bank Financial

Share on StockTwits

National Bank Financial reiterated their sector perform rating on shares of Alaris Royalty (TSE:AD) in a research note released on Thursday morning, BayStreet.CA reports. National Bank Financial currently has a C$18.00 target price on the stock. National Bank Financial also issued estimates for Alaris Royalty’s Q4 2019 earnings at $0.41 EPS.

A number of other brokerages also recently weighed in on AD. Raymond James reissued a market perform rating and set a C$19.00 target price on shares of Alaris Royalty in a research note on Wednesday, March 6th. Cormark lifted their target price on shares of Alaris Royalty from C$21.50 to C$22.00 in a research note on Thursday, March 7th. CIBC lifted their target price on shares of Alaris Royalty from C$19.00 to C$22.00 in a research note on Thursday, March 7th. Finally, Royal Bank of Canada reissued an outperform rating and set a C$24.00 target price on shares of Alaris Royalty in a research note on Monday, March 4th.

AD stock opened at C$19.34 on Thursday. The firm has a market cap of $705.83 million and a PE ratio of 9.43. Alaris Royalty has a 52-week low of C$15.62 and a 52-week high of C$21.41. The company has a quick ratio of 1.86, a current ratio of 3.84 and a debt-to-equity ratio of 36.91.

Alaris Royalty (TSE:AD) last released its quarterly earnings results on Monday, May 6th. The company reported C$0.42 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of C$0.41 by C$0.01. The business had revenue of C$27.66 million for the quarter, compared to the consensus estimate of C$27.20 million. On average, research analysts predict that Alaris Royalty will post 1.7499999 EPS for the current year.

The company also recently announced a monthly dividend, which will be paid on Monday, June 17th. Investors of record on Monday, June 17th will be paid a dividend of $0.1375 per share. This represents a $1.65 dividend on an annualized basis and a yield of 8.53%. The ex-dividend date of this dividend is Thursday, May 30th. Alaris Royalty’s dividend payout ratio is presently 80.49%.

In other Alaris Royalty news, Director Jack Chuck Lee sold 2,500 shares of Alaris Royalty stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of C$18.61, for a total value of C$46,525.00. Following the completion of the sale, the director now directly owns 219,087 shares of the company’s stock, valued at C$4,077,209.07. Also, Senior Officer Curtis James Krawetz sold 6,000 shares of Alaris Royalty stock in a transaction on Friday, May 17th. The shares were sold at an average price of C$18.61, for a total transaction of C$111,660.00. Following the completion of the sale, the insider now directly owns 36,721 shares of the company’s stock, valued at C$683,377.81. Insiders have sold 11,500 shares of company stock valued at $215,125 in the last three months.

About Alaris Royalty

Alaris Royalty Corp. is a private equity firm specializing in management buyouts, growth capital, lower & middle market, later stage, industry consolidation, growth capital, and mature investments. The firm does not invest in turnarounds and start-ups. It prefers to invest in the companies based in all industries except for those with a declining asset base, such as oil and gas resource companies, or any industry that carry the risk of obsolescence such as high tech and focuses on business services, professional services, information services, healthcare services, distribution & logistics, industrials, consumer products.

Recommended Story: Certificate of Deposit (CD)

Receive News & Ratings for Alaris Royalty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaris Royalty and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Elastic  Rating Lowered to Sell at Zacks Investment Research
Elastic Rating Lowered to Sell at Zacks Investment Research
Diplomat Pharmacy  Stock Rating Lowered by Zacks Investment Research
Diplomat Pharmacy Stock Rating Lowered by Zacks Investment Research
Dicerna Pharmaceuticals  Rating Lowered to Sell at Zacks Investment Research
Dicerna Pharmaceuticals Rating Lowered to Sell at Zacks Investment Research
Eastgroup Properties  Rating Lowered to Hold at Zacks Investment Research
Eastgroup Properties Rating Lowered to Hold at Zacks Investment Research
Zacks Investment Research Upgrades NOW  to “Buy”
Zacks Investment Research Upgrades NOW to “Buy”
Zacks Investment Research Downgrades Endologix  to Hold
Zacks Investment Research Downgrades Endologix to Hold


© 2006-2019 Ticker Report